DealsJul 14, 2026, 06:03 AM
Spero Therapeutics Secures $105M Financing for SP001, Extends Runway
AI Summary
Spero Therapeutics announced a $105 million non-recourse non-dilutive royalty financing transaction with Healthcare Royalty (HCRx), a KKR business. This funding will primarily advance SP001, Spero's first immunology drug candidate, into Phase 2 development. The deal unlocks immediate value from future Utebzi milestones and royalties, significantly strengthening Spero's balance sheet and extending its cash runway into the second half of 2029. This strategic move positions the company for its immunology-focused growth strategy, following the recent U.S. approval of Utebzi.
Key Highlights
- Spero Therapeutics secured a $105 million non-recourse non-dilutive royalty financing transaction.
- Proceeds will primarily support Phase 2 development of SP001, its lead immunology drug candidate.
- The financing extends Spero's cash runway guidance into the second half of 2029.
- Healthcare Royalty (HCRx) will receive a portion of future Utebzi milestone and royalty payments.
- Spero retains 35% of subsequent GSK payments related to Utebzi sales after HCRx repayment.
- The financing was concurrent with an exclusive license agreement with Innovent Biologics for SP001.
Price Impact
More from SPRO